Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. The most common clinical presentations of thyroid injury induced by pembrolizumab are destructive thyroiditis and overt hypothyroidism. Herein, we presented a case of pembrolizumab induced hypothyroidism.
Pembrolizumab immune checkpoint inhibitors lung cancer hypothyroidism PD-1 non-small cell lung
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Case Reports |
Yazarlar | |
Yayımlanma Tarihi | 1 Nisan 2022 |
Gönderilme Tarihi | 24 Şubat 2022 |
Kabul Tarihi | 9 Mart 2022 |
Yayımlandığı Sayı | Yıl 2022 Cilt: 4 - Supplement 1 |